ZURICH, May 10 (Reuters) - Austrian biotech company Intercell and German gorp Boehringer Ingelheim Vetmedica have struck a deal to develop animal vaccines, marking Intercell's first move outside human health. Intercell, which is developing vaccines for a number of infectious diseases, will get upfront, option and milestone payments as well as royalties on product sales, it said on Monday. Boehringer Ingelheim Vetmedica will have the right to use certain antigens from Intercell's antigen identification programme (API) to develop animal vaccines, Intercell said. Intercell, the only major independent vaccine maker left in Europe aside from Dutch company Crucell, last year started to sell its Japanese Encephalitis vaccine Ixiaro, distributed with Swiss group Novartis. The group is also developing a vaccine for S.aureus, a type of bacteria that can cause serious infection, with Merck KGaA and a vaccine patch against traveller's diarrhea, which it is developing with GlaxoSmithKline. (Reporting by Katie Reid; Editing by Dan Lalor) Keywords: INTERCELL/ (Zurich Newsroom, firstname.lastname@example.org, +41 58 306 7336) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.